Insider Selling: Natera (NASDAQ:NTRA) CFO Sells 602 Shares of Stock

Key Points

• Natera's CFO, Michael Burkes Brophy, sold 602 shares at an average price of $187.95, totaling $113,145.90, reducing his ownership by 0.85% to 70,109 shares.
• The company's recent quarterly earnings reported an EPS of ($0.74), missing expectations, but revenue increased 32.2% year-over-year, reaching $546.60 million.
• Natera holds a market cap of $25.81 billion and has received varying analyst ratings, with targets ranging from $170.00 to $200.00 amidst overall positive sentiment.

Natera, Inc. (NASDAQ:NTRA - Get Free Report) CFO Michael Burkes Brophy sold 602 shares of the company's stock in a transaction that occurred on Tuesday, October 21st. The shares were sold at an average price of $187.95, for a total value of $113,145.90. Following the transaction, the chief financial officer owned 70,109 shares of the company's stock, valued at approximately $13,176,986.55. This represents a 0.85% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Michael Burkes Brophy also recently made the following trade(s):

• On Tuesday, September 30th, Michael Burkes Brophy sold 2,491 shares of Natera stock. The shares were sold at an average price of $162.05, for a total value of $403,666.55.
• On Tuesday, July 29th, Michael Burkes Brophy sold 3,045 shares of Natera stock. The shares were sold at an average price of $137.40, for a total value of $418,383.00.
• On Monday, July 28th, Michael Burkes Brophy sold 2,019 shares of Natera stock. The shares were sold at an average price of $139.81, for a total value of $282,276.39.
• On Thursday, July 24th, Michael Burkes Brophy sold 755 shares of Natera stock. The shares were sold at an average price of $139.50, for a total value of $105,322.50.

Natera Stock Performance

Shares of Natera stock traded up $1.14 during midday trading on Wednesday, reaching $188.02. 1,333,479 shares of the company's stock traded hands, compared to its average volume of 1,160,110. The stock has a 50 day moving average of $169.97 and a 200-day moving average of $159.37. The company has a market cap of $25.81 billion, a PE ratio of -98.44 and a beta of 1.74. Natera, Inc. has a 12 month low of $117.27 and a 12 month high of $196.63.

Natera (NASDAQ:NTRA - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The medical research company reported ($0.74) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.14). The firm had revenue of $546.60 million during the quarter, compared to the consensus estimate of $476.84 million. Natera had a negative return on equity of 22.22% and a negative net margin of 12.89%.Natera's revenue for the quarter was up 32.2% compared to the same quarter last year. During the same quarter last year, the company posted ($0.30) EPS. Natera has set its FY 2025 guidance at EPS. On average, equities analysts anticipate that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have issued reports on the company. Evercore ISI upgraded Natera to a "strong-buy" rating and set a $170.00 price objective for the company in a report on Monday, July 28th. Morgan Stanley reissued an "overweight" rating and issued a $195.00 target price on shares of Natera in a research note on Sunday, August 10th. Cowen reissued a "buy" rating on shares of Natera in a research note on Friday, August 8th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Natera in a research report on Wednesday, October 8th. Finally, Canaccord Genuity Group reissued a "buy" rating and issued a $200.00 target price on shares of Natera in a research report on Tuesday, October 14th. One research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $196.81.

Institutional Trading of Natera

Several institutional investors and hedge funds have recently added to or reduced their stakes in NTRA. GAMMA Investing LLC raised its stake in Natera by 32.3% during the 1st quarter. GAMMA Investing LLC now owns 848 shares of the medical research company's stock valued at $120,000 after purchasing an additional 207 shares during the period. Narwhal Capital Management grew its holdings in Natera by 53.8% during the 1st quarter. Narwhal Capital Management now owns 9,993 shares of the medical research company's stock valued at $1,413,000 after buying an additional 3,494 shares in the last quarter. Asset Management One Co. Ltd. purchased a new position in Natera during the 1st quarter valued at approximately $6,753,000. Chevy Chase Trust Holdings LLC grew its holdings in Natera by 3.0% during the 1st quarter. Chevy Chase Trust Holdings LLC now owns 566,549 shares of the medical research company's stock valued at $80,116,000 after buying an additional 16,678 shares in the last quarter. Finally, Golden State Wealth Management LLC grew its holdings in Natera by 103.4% during the 1st quarter. Golden State Wealth Management LLC now owns 1,017 shares of the medical research company's stock valued at $144,000 after buying an additional 517 shares in the last quarter. Institutional investors own 99.90% of the company's stock.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.